Neurocrine Inks $575 Mil. Deal With Abbott To Develop and Sell Gynecologic, Elagolix
This article was originally published in The Pink Sheet Daily
Executive Summary
Elagolix could be the first oral drug approved for endometriosis that does not have severe side effects.